{"id":46112,"date":"2022-02-06T23:07:13","date_gmt":"2022-02-07T04:07:13","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=46112"},"modified":"2022-02-06T23:07:13","modified_gmt":"2022-02-07T04:07:13","slug":"can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112","title":{"rendered":"Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact"},"content":{"rendered":"<p>Today there is a massive $13.6 billion neurostimulation devices market developing for the ongoing study of the vast arrays of the brain\u2019s neural connections. (1) The diagnostic electrode technology currently used to detect neurological disorders is the same that was developed way back in the 1960s. (2) This is where NeuroOne Medical Technologies (NASDAQ:NMTC) comes into play.<\/p>\n<p><strong>NeuroOne Medical Technologies Corporation (NASDAQ:NMTC)<\/strong>\u00a0is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs.<\/p>\n<p>Mayo Clinic began testing NeuroOne\u2019s technology in preclinical models and clinical research in 2015 and is presently a top shareholder. (3) NeuroOne Evo electrode product line is complementary to Zimmer Biomet\u2019s ROSA ONE Brain platform used in minimally invasive neurosurgeries. (3) NeuroOne has received FDA approval for their Evo Cortical and sEEG Electrodes. (4) This innovative company is behind the scenes bringing what once could be considered science-fiction-inspired technologies to the brink of creation or they already have it in development. And thanks to NeuroOne\u2019s strategic partnerships they expect their technologies to be widely adopted in the near future.\u00a0<a href=\"https:\/\/biotechmarketreporter.com\/behind-the-miracle-therapies-of-neuroscience\/?utm_source=bullzeyemedia&amp;utm_medium=affiliate&amp;utm_campaign=nmtcz_us&amp;_ef_transaction_id=ffa7da52c5d14a5dbcaaf910f4958b4c\" target=\"_blank\" rel=\"noopener\"><strong>Click\u00a0HERE\u00a0to read more about why The Future of Neuroscience is Built on This Thin Film Electrode Technology<\/strong><\/a><\/p>\n<p>Other companies in NeuroOne Medical Tech\u2019s space includes ENDRA Life Sciences (NASDAQ:NDRA), Second Sight Medical (NASDAQ:EYES), Bluejay Diagnostics (NASDAQ:BJDX), Motus GI Hldgs (NASDAQ:MOTS), and Tivic Health Systems (NASDAQ:TIVC). It could be interesting to research if Tesla\u2019s (NASDAQ:TSLA) co-founder Elon Musk\u2019s company Neuralink and NeuroOne Medical Technologies (NASDAQ:NMTC) have anything in common. As always conduct your own due diligence.<\/p>\n<p>Sources:<\/p>\n<p>Source 1:\u00a0https:\/\/www.gminsights.com\/pressrelease\/neurostimulation-devices-market-size<\/p>\n<p>Source 2:\u00a0https:\/\/n1mtc.com\/investorsSource<\/p>\n<p>Source 3: https:\/\/seekingalpha.com\/article\/4470806-neuroone-nmtc-stock-thin-film-electrodes-neurological-conditions<\/p>\n<p>Source 4: https:\/\/www.mpo-mag.com\/contents\/view_breaking-news\/2021-12-08\/fda-clears-neuroone-medical-technologies-evo-seeg-electrode\/<\/p>\n<p>Additional Sources:<\/p>\n<p>https:\/\/www.mayoclinic.org\/about-mayo-clinic<\/p>\n<p>https:\/\/www.yahoo.com\/now\/neuroone-medical-technologies-corporation-announces-130000582.html<\/p>\n<p>https:\/\/www.healthaffairs.org\/doi\/10.1377\/hlthaff.2020.01118<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Today there is a massive $13.6 billion neurostimulation devices market developing for the ongoing study of the vast arrays of the brain\u2019s neural connections. (1) [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":46113,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236],"tags":[16219,12760,16221,16218,16220,16222,458],"stock_ticker":[],"class_list":["post-46112","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-bjdx","tag-eyes","tag-mots","tag-nmtc","tag-tivc","tag-ts","tag-tsla","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Today there is a massive $13.6 billion neurostimulation devices market developing for the ongoing study of the vast arrays of the brain\u2019s neural connections. (1) [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-07T04:07:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/02\/human-brain-blue-background-hemisphere-is-responsible-logic.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"1000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact\",\"datePublished\":\"2022-02-07T04:07:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112\"},\"wordCount\":365,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/02\/human-brain-blue-background-hemisphere-is-responsible-logic.jpg\",\"keywords\":[\"BJDX\",\"EYES\",\"MOTS\",\"NMTC\",\"TIVC\",\"TS\",\"TSLA\"],\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112\",\"name\":\"Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/02\/human-brain-blue-background-hemisphere-is-responsible-logic.jpg\",\"datePublished\":\"2022-02-07T04:07:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/02\/human-brain-blue-background-hemisphere-is-responsible-logic.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/02\/human-brain-blue-background-hemisphere-is-responsible-logic.jpg\",\"width\":1500,\"height\":1000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112","og_locale":"en_US","og_type":"article","og_title":"Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact - Wall Street PR","og_description":"Today there is a massive $13.6 billion neurostimulation devices market developing for the ongoing study of the vast arrays of the brain\u2019s neural connections. (1) [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2022-02-07T04:07:13+00:00","og_image":[{"width":1500,"height":1000,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/02\/human-brain-blue-background-hemisphere-is-responsible-logic.jpg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact","datePublished":"2022-02-07T04:07:13+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112"},"wordCount":365,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/02\/human-brain-blue-background-hemisphere-is-responsible-logic.jpg","keywords":["BJDX","EYES","MOTS","NMTC","TIVC","TS","TSLA"],"articleSection":["Business"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112","url":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112","name":"Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/02\/human-brain-blue-background-hemisphere-is-responsible-logic.jpg","datePublished":"2022-02-07T04:07:13+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/02\/human-brain-blue-background-hemisphere-is-responsible-logic.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/02\/human-brain-blue-background-hemisphere-is-responsible-logic.jpg","width":1500,"height":1000},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/can-neuroone-medical-technologies-nasdaqnmtc-drive-the-shift-from-science-fiction-to-science-fact-46112#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/46112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=46112"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/46112\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/46113"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=46112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=46112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=46112"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=46112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}